[
  {
    "ts": null,
    "headline": "Why Johnson & Johnson's Share Price Is Popping This Month",
    "summary": "Johnson & Johnson had strong Q3 results and reported an important acquisition.",
    "url": "https://finnhub.io/api/news?id=4c23b55e511aabc13eb4f3cf2a1c482ac5cae020ca377f78be800941105a2f02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763573086,
      "headline": "Why Johnson & Johnson's Share Price Is Popping This Month",
      "id": 137548652,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson had strong Q3 results and reported an important acquisition.",
      "url": "https://finnhub.io/api/news?id=4c23b55e511aabc13eb4f3cf2a1c482ac5cae020ca377f78be800941105a2f02"
    }
  },
  {
    "ts": null,
    "headline": "Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study",
    "summary": "MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.",
    "url": "https://finnhub.io/api/news?id=908076479ac0577d11ea4f1875a39845e1f30879e5a3ad0d4e4f290650a2f6d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763567520,
      "headline": "Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study",
      "id": 137548653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.",
      "url": "https://finnhub.io/api/news?id=908076479ac0577d11ea4f1875a39845e1f30879e5a3ad0d4e4f290650a2f6d5"
    }
  },
  {
    "ts": null,
    "headline": "Knee Replacement Surgery Market Analysis Report 2025-2035: Stryker, Zimmer Biomet, B. Braun, and DePuy Synthes Lead Innovations by Continually Innovating and Improving Patient Outcomes",
    "summary": "Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry",
    "url": "https://finnhub.io/api/news?id=149c9b39f59806d31eb83e6021f4f6dbbc0ec75aca23111437bdd1c507ccb938",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763563680,
      "headline": "Knee Replacement Surgery Market Analysis Report 2025-2035: Stryker, Zimmer Biomet, B. Braun, and DePuy Synthes Lead Innovations by Continually Innovating and Improving Patient Outcomes",
      "id": 137546387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry",
      "url": "https://finnhub.io/api/news?id=149c9b39f59806d31eb83e6021f4f6dbbc0ec75aca23111437bdd1c507ccb938"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
    "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
    "url": "https://finnhub.io/api/news?id=930613e7be8028dfed893ae65e3fd828783bf46c3808cb88ce2e8451a64999ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763561280,
      "headline": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
      "id": 137548645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
      "url": "https://finnhub.io/api/news?id=930613e7be8028dfed893ae65e3fd828783bf46c3808cb88ce2e8451a64999ba"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=53b73cae6ca86faff4d61d662a448592b15ab9a53a3785a823dc200f8cb6df2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763560805,
      "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
      "id": 137548655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=53b73cae6ca86faff4d61d662a448592b15ab9a53a3785a823dc200f8cb6df2c"
    }
  },
  {
    "ts": null,
    "headline": "BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU",
    "summary": "Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms",
    "url": "https://finnhub.io/api/news?id=cf7c800ba2f917952b5778d75a61e1d057ce6a947f9acd6bbd1bc76f68093b96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763560380,
      "headline": "BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU",
      "id": 137546388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms",
      "url": "https://finnhub.io/api/news?id=cf7c800ba2f917952b5778d75a61e1d057ce6a947f9acd6bbd1bc76f68093b96"
    }
  },
  {
    "ts": null,
    "headline": "Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?",
    "summary": "Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.",
    "url": "https://finnhub.io/api/news?id=661f1fdfcfaf5c9d9e51fdaa589aa1b4b25b0763a9d0ceba347d44a94cb71be5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763557320,
      "headline": "Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?",
      "id": 137546389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.",
      "url": "https://finnhub.io/api/news?id=661f1fdfcfaf5c9d9e51fdaa589aa1b4b25b0763a9d0ceba347d44a94cb71be5"
    }
  },
  {
    "ts": null,
    "headline": "Why VYM Is Not A Good Alternative To SCHD",
    "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
    "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763542800,
      "headline": "Why VYM Is Not A Good Alternative To SCHD",
      "id": 137546014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990349253/image_1990349253.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
      "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32"
    }
  }
]